Ann: Phosphagenics Arbitration Award Issued, page-178

PM

Could have something to do with this approval this year for Mylan Dapto and being placed under their label as per a prev recent POH Ann. 

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205037

I am assuming if our agreement has strict requirements re a generic Dapto being approved and sold then it could imply that mylan have not adhered to developing a TPM Dapto as per agreement opting to produce generic first against terms of agreement. 

Hence why POH indicate they have to weigh up their options on that as a breach maybe.